Real‐world persistence of erenumab for preventive treatment of chronic and episodic migraine: Retrospective real‐world study. Issue 1 (22nd November 2021)

• Record Type: Journal Article
• Authors: Gladstone, Jonathan; Chhibber, Sameer; Minhas, Jagdeep; Neish, Calum S.; Power, G. Sarah; Lan, Zhiyi; Rochdi, Driss; Lanthier‐Martel, Jessica; Bastien, Natacha
• Is Part Of: Headache. Volume 62:Issue 1(2022)
• Page Start: 78
• Page End: 88
• Publication Date: 2021-11-22
• Subjects: dose -- erenumab -- migraine -- persistence -- prophylactic; Headache -- Periodicals; Headache -- Periodicals; 616.8491
• DOI: 10.1111/head.14218
• Languages: English
• ISSNs: 0017-8748

Abstract

Abstract: Objective: To describe the real‐world treatment persistence (defined as the continuation of medication for the prescribed treatment duration), demographics and clinical characteristics, and treatment patterns for patients prescribed erenumab for migraine prevention in Canada. Background: The effectiveness of prophylactic migraine treatments is often undermined by poor treatment persistence. In clinical trials, erenumab has demonstrated efficacy and tolerability as a preventive treatment, but less is known about the longer term treatment persistence with erenumab. Methods: This is a real‐world retrospective cohort study where a descriptive analysis of secondary patient data was conducted. Enrollment and prescription data were extracted from a patient support program for a cohort of patients prescribed erenumab in Canada between September 2018 and December 2019 and analyzed for persistence, baseline demographics, clinical characteristics, and treatment patterns. Descriptive analyses and unadjusted Kaplan–Meier (KM) curves were used to summarize the persistence and dose escalation/de‐escalation at different timepoints. Results: Data were analyzed for 14, 282 patients. Median patient age was 47 years, 11, 852 (83.0%) of patients were female, and 9443 (66.1%) had chronic migraine at treatment initiation. Based on KM methods, 71.0% of patients overall were persistent to erenumab 360 days after treatment initiation. Within 360 days of treatment initiation, it is estimated that 59.3% (KM‐derived) of patients who initiated erenumab at 70 mg escalated to 140 mg, and 4.4% (KM‐derived) of patients who initiated at 140 mg de‐escalated to 70 mg. Conclusions: The majority of patients prescribed erenumab remained persistent for at least a year after treatment initiation, and most patients initiated or escalated to a 140 mg dose. These results suggest that erenumab is well tolerated, and its uptake as a new class of prophylactic treatment for migraine in real‐world clinical practice is not likely to be undermined by poor persistence when coverage for erenumab is easily available.